TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9593066

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 45

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 45
Study: 7528305

Group type: EXPERIMENTAL
Intervention: temocapril
Number of subjects: 10

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study: 3246167

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (CRO: Rocephin) 100 mg/kg/day, once daily
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ampicillin 160 mg/kg/day and chloramphenicol (AMCL) 100 mg/kg/day, every 6 h
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (CRO)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ampicillin and chloramphenicol (AMCL)
Number of subjects: 100
Study: 29530747

Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen (Ofirmev)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 29199345

Group type: EXPERIMENTAL
Intervention: 3D printing implant template (TDPIT group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional implant template (CIT group)
Number of subjects: 30
Study: 26259598

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus bevacizumab (CT + B)
Number of subjects: 237

Group type: COMPARATOR
Intervention: Chemotherapy (CT) alone
Number of subjects: 237
Study: 23971383

Group type: EXPERIMENTAL
Intervention: alpha-dihydroergocryptine
Number of subjects: 171

Group type: COMPARATOR
Intervention: cabergoline
Number of subjects: 171
Study: 20373906

Group type: EXPERIMENTAL
Intervention: Prodose Adaptive Aerosol Delivery (AAD) System
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Home delivery of medication
Number of subjects: 19
Study: 18230068

Group type: EXPERIMENTAL
Intervention: remifentanil 0.5 microg.kg(‐1)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: remifentanil 1 microg.kg(‐1)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: alfentanil 15 microg.kg(‐1)
Number of subjects: 120

Group type: COMPARATOR
Intervention: saline 5 ml
Number of subjects: 120
Study: 15126521

Group type: EXPERIMENTAL
Intervention: Type 1 diabetic patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matched nondiabetic controls
Number of subjects: 0
Study: 11806474

Group type: EXPERIMENTAL
Intervention: Prime & Bond 2.1
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Prime & Bond NT
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Experimental (unfilled NT)
Number of subjects: 3
Study: 9483299

Group type: EXPERIMENTAL
Intervention: Bubble CPAP
Number of subjects: 10

Group type: COMPARATOR
Intervention: Ventilator-derived CPAP
Number of subjects: 10
Study: 7520248

Group type: EXPERIMENTAL
Intervention: Humans immunized with rgp120
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chimpanzees immunized with rgp120
Number of subjects: 0
Study: 2844887

Group type: EXPERIMENTAL
Intervention: Wiping transducers with alcohol between uses
Number of subjects: 2202

Group type: COMPARATOR
Intervention: Sterilizing with ethylene oxide
Number of subjects: 2202
Study: 31919102

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 384
Study: 31701652

Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG) based strategy (SBI)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Triple-drug chemotherapy with lipiodol diameter ratio values between 1 and 3
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Lipiodol ≤10 mL
Number of subjects: 112

Group type: COMPARATOR
Intervention: SBI (Indocyanine green based strategy)
Number of subjects: 112
Study: 29151359

Group type: EXPERIMENTAL
Intervention: Osimertinib (80 mg once daily)
Number of subjects: 556

Group type: COMPARATOR
Intervention: Standard EGFR-TKIs (gefitinib 250 mg once daily or erlotinib 150 mg once daily)
Number of subjects: 556
Study: 25758619

Group type: EXPERIMENTAL
Intervention: Misoprostol vaginal insert (MVI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dinoprostone vaginal insert (DVI)
Number of subjects: 0
Study: 24486637

Group type: EXPERIMENTAL
Intervention: 200 units of onabotulinum toxin A (Botox A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sacral neuromodulation (InterStim) therapy
Number of subjects: 0
Study: 22520521

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 2201

Group type: COMPARATOR
Intervention: Medical treatment (MED)
Number of subjects: 2201

Group type: EXPERIMENTAL
Intervention: PCI
Number of subjects: 2201

Group type: COMPARATOR
Intervention: MED
Number of subjects: 2201
Study: 20708427

Group type: EXPERIMENTAL
Intervention: Hand circumference measurement
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Predictive regression model based on hand circumference
Number of subjects: 100
Study: 17977931

Group type: EXPERIMENTAL
Intervention: Anodyne monochromatic infrared photo energy (MIRE) treatment, used at home every day for 40 min for 90 days.
Number of subjects: 69

Group type: COMPARATOR
Intervention: Sham treatment, used at home every day for 40 min for 90 days.
Number of subjects: 69
Study: 16214012

Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg/d)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 11523885

Group type: EXPERIMENTAL
Intervention: Cantilever resin‐bonded bridges (RBBs)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional partial dentures (RPDs)
Number of subjects: 60
Study: 9781975

Group type: EXPERIMENTAL
Intervention: trimetazidine (20 mg 3 times daily)
Number of subjects: 15

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 15
Study: 7876047

Group type: EXPERIMENTAL
Intervention: Intravenous streptokinase (IVSK) 1.5 million units within 6 hours of onset of chest pain, along with beta-blockers, aspirin, and heparin unless contraindicated.
Number of subjects: 160

Group type: COMPARATOR
Intervention: Conventional therapy without IVSK.
Number of subjects: 160
Study: 2465851

Group type: EXPERIMENTAL
Intervention: Cocaine and adrenaline combination
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cocaine alone
Number of subjects: 30
Study: 31915181

Group type: EXPERIMENTAL
Intervention: Pare de fumar conosco web-based smoking cessation decision-making tool
Number of subjects: 85
Study: 30919670

Group type: EXPERIMENTAL
Intervention: Melatonin (0.1 to 0.2 mg/kg, PO, q 12 h for 7 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (150 mg of lactose powder in a capsule, PO, q 12 h for 7 days)
Number of subjects: 20
Study: 28746195

Group type: EXPERIMENTAL
Intervention: Facial candling treatment
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (no treatment given)
Number of subjects: 66
Study: 26079533

Group type: EXPERIMENTAL
Intervention: Ketamine infusion at a rate of 2 μg/kg/min until 48 h after surgery
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (saline infusion)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Ketamine infusion
Number of subjects: 36
Study: 23542639

Group type: EXPERIMENTAL
Intervention: NRTI arm (abacavir/zidovudine/lamivudine)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: PI arm (lopinavir/ritonavir/zidovudine/lamivudine)
Number of subjects: 54
Study: 23437535

Group type: EXPERIMENTAL
Intervention: Intradermally administered inactivated poliovirus vaccine (0.1 mL) using Biojector 2000
Number of subjects: 471

Group type: COMPARATOR
Intervention: Intramuscularly administered inactivated poliovirus vaccine (0.5 mL) using a pre-filled syringe
Number of subjects: 471
Study: 19343272

Group type: EXPERIMENTAL
Intervention: Alendronate 70 mg once-weekly
Number of subjects: 560

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 560
Study: 16635559

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Behavior therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15566656

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus cisplatin (GP arm)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Gemcitabine plus vinorelbine (GN arm)
Number of subjects: 82
Study: 11584657

Group type: EXPERIMENTAL
Intervention: Tafenoquine
Number of subjects: 411

Group type: COMPARATOR
Intervention: Primaquine
Number of subjects: 411
Study: 9160928

Group type: EXPERIMENTAL
Intervention: KTP laser tonsillectomy
Number of subjects: 38

Group type: COMPARATOR
Intervention: Standard dissection tonsillectomy
Number of subjects: 38
Study: 7955810

Group type: EXPERIMENTAL
Intervention: Fluvoxamine (100 to 150 mg daily for 16 days)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (single oral dose of diazepam 10 mg)
Number of subjects: 8
Study: 31359283

Group type: EXPERIMENTAL
Intervention: MRI-guided surgery
Number of subjects: 138

Group type: COMPARATOR
Intervention: Wire-localized surgery
Number of subjects: 138

Group type: COMPARATOR
Intervention: Mammography
Number of subjects: 138
Study: 29570894

Group type: EXPERIMENTAL
Intervention: CTI with concomitant PVI
Number of subjects: 50

Group type: COMPARATOR
Intervention: CTI-only
Number of subjects: 50
Study: 26003419

Group type: EXPERIMENTAL
Intervention: Group cognitive-behavioral therapy (CBT) for children
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Group CBT for children plus parent training
Number of subjects: 61

Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 61
Study: 25283586

Group type: EXPERIMENTAL
Intervention: LNG-IUS
Number of subjects: 44

Group type: COMPARATOR
Intervention: GnRHa
Number of subjects: 44
Study: 22497341

Group type: EXPERIMENTAL
Intervention: Sustained cognitive performance
Number of subjects: 29

Group type: COMPARATOR
Intervention: Cognitively demanding intervention
Number of subjects: 29
Study: 19919878

Group type: EXPERIMENTAL
Intervention: Enoxaparin 20mg twice daily for 14 days, started 24-36 hours after surgery
Number of subjects: 151

Group type: COMPARATOR
Intervention: Intermittent pneumatic compression (IPC)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 151

Group type: COMPARATOR
Intervention: IPC
Number of subjects: 151
Study: 18990744

Group type: EXPERIMENTAL
Intervention: 1.5 g GTE per day for 12 months
Number of subjects: 136

Group type: COMPARATOR
Intervention: Control group without supplementation
Number of subjects: 136
Study: 16465662

Group type: EXPERIMENTAL
Intervention: Seal oil
Number of subjects: 43

Group type: COMPARATOR
Intervention: Soy oil
Number of subjects: 43
Study: 12809189

Group type: EXPERIMENTAL
Intervention: Anxiety Management group received training on relaxation strategies (deep breathing, progressive muscle relaxation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Attention Control group attended a lecture on the relation among stress, anxiety, and health
Number of subjects: 0
Study: 11232889

Group type: EXPERIMENTAL
Intervention: C-arm-supported CT fluoroscopy
Number of subjects: 40

Group type: COMPARATOR
Intervention: CT fluoroscopy alone
Number of subjects: 40
Study: 8857072

Group type: EXPERIMENTAL
Intervention: Moclobemide 200 mg b.d. for 14 days
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Selegiline 5 mg b.d. for 14 days
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Combined treatment with moclobemide and selegiline
Number of subjects: 24
Study: 1352497

Group type: EXPERIMENTAL
Intervention: Propranolol (highly lipophilic BAA, no PAA)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pindolol (moderately lipophilic BAA, strong PAA)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dilevalol (highly lipophilic BAA, weak PAA)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Salbutamol (full agonist)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: BAAs with PAA
Number of subjects: 12
Study: 6391231

Group type: EXPERIMENTAL
Intervention: Combination of clindamycin and tobramycin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cefamandole or cefoxitin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moxalactam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tobramycin plus clindamycin
Number of subjects: 0
Study: 30153781

Group type: EXPERIMENTAL
Intervention: Protocol-guided strategy using stroke volume variation to guide administration of bolus fluid
Number of subjects: 700

Group type: COMPARATOR
Intervention: Usual care fluid administration
Number of subjects: 700
Study: 27128738

Group type: EXPERIMENTAL
Intervention: Pelican instrument for asthma management
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Parent and nurse satisfaction with the program
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: SMART principles for goal formulation
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Traditional management aspects
Number of subjects: 42
Study: 24783923

Group type: EXPERIMENTAL
Intervention: Standardized treatment with TCM combined with WM (oral Chinese decoctions three times daily for 4 weeks)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Non-standardized treatment with TCM combined with WM (oral Chinese decoction for promotion of blood circulation for 4 weeks)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Both groups (standardized and non-standardized treatment)
Number of subjects: 90
Study: 21801088

Group type: EXPERIMENTAL
Intervention: Lip adhesion
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: H (‐) group (no Hotz's plate)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: H (+) group (with Hotz's plate)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: LA‐H group (lip adhesion and Hotz's plate)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Noncleft group
Number of subjects: 53
Study: 19347843

Group type: EXPERIMENTAL
Intervention: Highly active antiretroviral therapy (ART)
Number of subjects: 1156

Group type: EXPERIMENTAL
Intervention: Noncompliance correction using inverse probability-of-censoring weights
Number of subjects: 1156
Study: 17447222

Group type: EXPERIMENTAL
Intervention: Reconcile (fluoxetine, 1 to 2 mg/kg/day) plus behavior management
Number of subjects: 0
Study: 14716221

Group type: EXPERIMENTAL
Intervention: Combination of low-dose nifedipine GITS 20 mg and losartan 50 mg
Number of subjects: 300

Group type: COMPARATOR
Intervention: Losartan 50 mg
Number of subjects: 300

Group type: COMPARATOR
Intervention: Nifedipine GITS 20 mg
Number of subjects: 300
Study: 12635758

Group type: EXPERIMENTAL
Intervention: Paracervical block with 1% lignocaine
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo group (paracervical block with sterile water)
Number of subjects: 142
Study: 9855086

Group type: EXPERIMENTAL
Intervention: Intravenous omeprazole infusion (80 mg + 8 mg/h) for 24 hours followed by 8, 4 or 2 mg/h.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intravenous omeprazole infusion (80 mg + 8 mg/h) for 3 days followed by oral omeprazole 20 mg once daily.
Number of subjects: 24
Study: 7584296

Group type: EXPERIMENTAL
Intervention: Recall and recognition tasks with varying word frequency
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Position judgements about list items
Number of subjects: 0
Study: 2607520

Group type: EXPERIMENTAL
Intervention: Accutracker blood pressure monitor
Number of subjects: 14
Study: 977834

Group type: EXPERIMENTAL
Intervention: Recorded speech samples from speakers (30 speakers total, 15 males and 15 females)
Number of subjects: 30
Study: 30727981

Group type: EXPERIMENTAL
Intervention: REPRINTS intergenerational health promotion program
Number of subjects: 891

Group type: EXPERIMENTAL
Intervention: Individuals aged 30-59 and over 60 years
Number of subjects: 891
Study: 28263212

Group type: EXPERIMENTAL
Intervention: Cabazitaxel (4 cycles of 25 mg/m2 + 2 cycles of 20 mg/m2) combined with 188Re-HEDP (40 MBq/kg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cabazitaxel (6 cycles of 25 mg/m2) combined with 188Re-HEDP (40 MBq/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cabazitaxel monotherapy
Number of subjects: 12
Study: 26497995

Group type: EXPERIMENTAL
Intervention: HALP ≥ 56.8
Number of subjects: 1332

Group type: COMPARATOR
Intervention: HALP < 56.8
Number of subjects: 1332
Study: 24079100

Group type: EXPERIMENTAL
Intervention: Full-mouth ultrasonic debridement (FMUD) for smokers (n = 10)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP) for smokers (n = 10)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) for non-smokers (n = 10)
Number of subjects: 30
Study: 21525848

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs) administered orally on single days to assess immediate effects on motor function.
Number of subjects: 0
Study: 19663371

Group type: EXPERIMENTAL
Intervention: Gore-Tex thyroplasty
Number of subjects: 30

Group type: COMPARATOR
Intervention: Silicone thyroplasty
Number of subjects: 30
Study: 16339819

Group type: EXPERIMENTAL
Intervention: Enrasentan (60‐90 mg/day)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Enalapril (10‐20 mg/day)
Number of subjects: 72
Study: 14724371

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle modification (ILM) program including dietary advice on low-fat diets, high antioxidants and high fiber intakes, yoga exercise, stress management and smoking cessation for 4 months.
Number of subjects: 44

Group type: COMPARATOR
Intervention: Conventional treatment with lipid-lowering drugs (control group).
Number of subjects: 44
Study: 10735925

Group type: EXPERIMENTAL
Intervention: Omeprazole, amoxycillin, clarithromycin for 7 days
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (omeprazole and placebos for 7 days)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Omeprazole, amoxycillin, clarithromycin
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 8766460

Group type: EXPERIMENTAL
Intervention: Counselling intervention (6 weekly sessions, educational and problem-solving components, conducted in the family home)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Counselling intervention
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 63
Study: 1417023

Group type: EXPERIMENTAL
Intervention: Copolymer of polyurethane membrane dressing
Number of subjects: 5

Group type: COMPARATOR
Intervention: Commercially available adhesive bandages
Number of subjects: 5
Study: 3921583

Group type: EXPERIMENTAL
Intervention: Combined enteral-parenteral nutrition (CN)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 20
Study: 30575059

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Ultrasonic scaler (US)
Number of subjects: 20
Study: 30547287

Group type: EXPERIMENTAL
Intervention: MCAF5352A (humanized monoclonal antibody targeting IL-17A and IL-17F)
Number of subjects: 0
Study: 27442130

Group type: EXPERIMENTAL
Intervention: Topical bromfenac
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 25124078

Group type: EXPERIMENTAL
Intervention: efavirenz
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: lower cost of clinic visits
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: improvement in CD4 percentage
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: care at Kayunga vs. Kangulamira
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: time on ART
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: patient satisfaction with care
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: improvements in total lymphocyte count
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: haemoglobin concentration
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: age at start of ART
Number of subjects: 325
Study: 23254183

Group type: COMPARATOR
Intervention: Family meals (always eating together at a table)
Number of subjects: 2383

Group type: COMPARATOR
Intervention: Daily consumption of F&V by parents
Number of subjects: 2383

Group type: COMPARATOR
Intervention: Cutting up fruit and vegetables for children
Number of subjects: 2383
Study: 21574683

Group type: EXPERIMENTAL
Intervention: Manual-guided treatment
Number of subjects: 76

Group type: COMPARATOR
Intervention: Usual care (nonmanualized treatment)
Number of subjects: 76
Study: 18050382

Group type: EXPERIMENTAL
Intervention: CF101 1.0 mg bid for 12 weeks
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: CF101 0.1 mg bid for 12 weeks
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: CF101 4.0 mg bid for 12 weeks
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: CF101 (all doses)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: A3AR expression levels
Number of subjects: 74
Study: 16681980

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy and radiotherapy concurrently
Number of subjects: 40

Group type: COMPARATOR
Intervention: Adjuvant thermotherapy and radiotherapy sequentially
Number of subjects: 40
Study: 12959789

Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 100
Study: 10682963

Group type: EXPERIMENTAL
Intervention: Scanning laser polarimetry
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Optical coherence tomography
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Visual function measurements
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Retinal nerve fiber layer structural measurements
Number of subjects: 78
Study: 9052110

Group type: EXPERIMENTAL
Intervention: Ward-based educational teaching package
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 0
Study: 8286801

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin staggered with calcium carbonate
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ciprofloxacin alone
Number of subjects: 12
Study: 3667020

Group type: EXPERIMENTAL
Intervention: Ultralong exercise (120 km march) for 24 hours
Number of subjects: 15
Study: 29722791

Group type: EXPERIMENTAL
Intervention: Intravenous NEPA (fosnetupitant 235 mg plus PALO 0.25 mg)
Number of subjects: 404

Group type: COMPARATOR
Intervention: Oral NEPA (netupitant 300 mg plus PALO 0.50 mg)
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Intravenous NEPA
Number of subjects: 404

Group type: COMPARATOR
Intervention: Oral NEPA
Number of subjects: 404
Study: 27382926

Group type: EXPERIMENTAL
Intervention: Acute Resistance Exercise (RE)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Reading session (Control)
Number of subjects: 35
Study: 24700136

Group type: EXPERIMENTAL
Intervention: Real dry needling
Number of subjects: 84

Group type: COMPARATOR
Intervention: Sham dry needling
Number of subjects: 84
Study: 24005613

Group type: EXPERIMENTAL
Intervention: PLD 50 mg/m² q28 and vandetanib 100 mg/d po
Number of subjects: 15
Study: 21505208

Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM) group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0